1887

Chapter 12 : Treatment of Intra-Abdominal Infections

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Treatment of Intra-Abdominal Infections, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap12-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap12-2.gif

Abstract:

Antibiotic therapy has assumed an increasingly important role in the management of intra-abdominal infections because of the replacement of surgical extirpation of inflamed and infected tissue by minimally invasive or percutaneous drainage procedures. This review describes the key findings of clinical trials performed to date and then describes settings in which antimicrobial agents may be the preferred antimicrobials. The organisms encountered in intra-abdominal infections are listed. Four quinolones have been examined in clinical trials for intra-abdominal infections: ciprofloxacin, trovafloxacin, clinafloxacin, and pefloxacin. These agents have considerable activity against the gram-negative facultative and aerobic organisms commonly encountered in intra-abdominal infections. The use of gentamicin as the sole agent with activity against aerobic gram-negative bacteria, however, may be probematic in intra-abdominal infections because anaerobic conditions may reduce its activity. Ciprofloxacin has little activity against and needs to be combined with an antianaerobic agent for empirical treatment of intra-abdominal infections. This study was designed to examine the efficacy of i.v. therapy and to explore conversion of therapeutic regimens to oral administration. The failure rates observed in general and with piperacillin-tazobactam (PIP/TAZO) in particular are markedly different from the other studies done with quinolones and the even larger number done with PIP/TAZO. The safety and efficacy of quinolone-based regimens in intra-abdominal infections has been clearly documented in clinical trials and is supported by the pharmacodynamics of these agents.

Citation: Solomkin J. 2003. Treatment of Intra-Abdominal Infections, p 217-225. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch12
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817817.chap12
1.1990. A randomized multicentre trial of pefloxacin plus metronidazole and gentamicin plus metronidazole in the treatment of severe intra-abdominal infections. Report from a Swedish Study Group. J. Antimicrob. Chemother. 26(Suppl. B):173180.
2. Aldridge, K. E.,, D. Ashcraft,, K. Cambre,, C. L. Pierson,, S. G. Jenkins,, and J. E. Rosenblatt. 2001. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob. Agents Chemother. 45:12381243.
3. Barie, P. S.,, N. V. Christou,, E. P. Dellinger,, W. R. Rout,, H. H. Stone,, and J . P. Waymack. 1990. Pathogenicity of the enterococcus in surgical infections. Ann. Surg. 212:155159.
4. Bauernfeind, A. 1993. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J. Antimicrob. Chemother. 31:505522.
5. Brismar, B.,, J. E. Akerlund,, S. Sjostedt ,, C. Johansson,, A. Tornqvist,, B. Backstrand,, H. Bang,, L. Andaker,, R. O. Gustafsson,, N. Darle,, M. Angeras,, A. Falk,, G. Tunevall,, B. Kasholm-Tengve,, T. Skau,, P. O. Nystrom,, T. Gasslander,, A. Hagelback,, B. Olsson-Liljequist,, A. E. Eklund,, and C. E. Nord. 1996. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group. Scand. J. Infect. Dis. 28:507512.
6. Brismar, B.,, A. S. Malmborg,, G. Tunevall,, V. Lindgren,, L. Bergman,, L. O. Mentzing,, P. O. Nystrom,, S. Ansehn,, B. Backstrand,, T. Skau,, L. Andaker,, P. O. Gustafsson,, B. Kasholm-Tengve,, L. Sjoberg,, B. Olsson-Liljequist,, A. E. Eklund,, and C. E. Nord. 1995. Meropenem versus imipenem/ cilastatin in the treatment of intra-abdominal infections. J. Antimicrob. Chemother. 35:139148.
7. Brismar, B.,, A. S. Malmborg,, G. Tunevall,, B. Wretlind,, L. Bergman,, L. O. Mentzing,, P. O. Nystrom,, E. Kihlstrom,, B. Backstrand,, and T. Skau. 1992. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob. Agents Chemother. 36:27662773.
8. Brook, I. 1993. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities. Antimicrob. Agents Chemother. 37:9971000.
9. Cohn, S. M.,, P. A. Lipsett,, T. G. Buchman,, W. G. Cheadle,, J. W. Milsom,, S. O'Marro,, A. E. Yellin,, S. Jungerwirth,, E. V. Rochefort,, D. C. Haverstock,, and S. F. Kowalsky. 2000. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann. Surg. 232:254262.
10. Dan, M.,, F. Serour,, and F. Poch 1992. Penetration of ciprofloxacin into human peritoneal tissue following a single oral dose of 750 milligrams. J. Chemother. 4:2729.
11. Dan, M.,, T. Zuabi,, C. Quassem,, and H. H. Rotmensch. 1992. Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams. Antimicrob. Agents Chemother. 36:677678.
12. Davis, R. L.,, J. R. Koup,, J. Williams-Warren,, A. Weber,, and A. L. Smith. 1985. Pharmacokinetics of three oral formulations of ciprofloxacin. Antimicrob. Agents Chemother. 28:7477.
13. Donahue, P. E.,, D. L. Smith,, A. E. Yellin,, S. J. Mintz,, F. Bur,, and D. R. Luke. 1998. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group. Am. J. Surg. 176(Suppl. 6A):53S61S.
14. Donahue, P. E.,, D. L. Smith,, A. E. Yellin,, S. J. Mintz,, F. Bur,, and D. R. Luke. 1998. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group. Am. J. Surg. 176(Suppl. 6A):53S61S.
15. Fink, M. P.,, Snydman,, D. R. Niederman,, M. S. Leeper,, K. V. Jr., Johnson,, R. H. Heard,, S. O. R. G. Wunderink,, J. W. Caldwell,, J. J. Schentag,, and G. A. Siami. For the severe Pneumonia Study Group. 1994. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob. Agents Chemother. 38:547557.
16. Reference deleted.
17. Geroulanos, S. J. 1995. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group. J. Antimicrob. Chemother. 36(Suppl. A):191205.
18. Lamp, K. C.,, C. D. Freeman,, N. E. Klutman,, and M. K. Lacy. 1999. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin. Pharmacokinet. 36: 353373.
19. Lau, A. H.,, K. Emmons,, and R. Seligsohn. Pharmacokinetics of intravenous metronidazole at different dosages in healthy subjects. Int. J. Clin. Pharmacol. Ther. Toxicol. 29:386390.
20. Luke, D. R.,, and J. Peterson. 1999. Treatment of complicated intra-abdominal infections: comparison of the tolerability and safety of intravenous/oral trovafloxacin versus intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid. Int. J. Clin. Pract. 53:166173.
21. Martin, C.,, B. Sastre,, M. N. Mallet,, B. Bruguerolle,, J. P. Brun,, P. De Micco, and F. Gouin. 1991. Pharmacokinetics and tissue penetration of a single 1,000-milligram, intravenous dose of metronidazole for antibiotic prophylaxis of colorectal surgery. Antimicrob. Agents Chemother. 35:26022605.
22. Montravers, P.,, R. Gauzit,, C. Muller,, J. P. Marmuse,, A. Fichelle,, and J. M. Desmonts. 1996. Emergence of antibioticresistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin. Infect. Dis. 23:486494.
23. Nguyen, M. H.,, V. L. Yu,, A. J. Morris,, L. McDermott,, M. W. Wagener,, L. Harrell and,, D. R. Snydman. 2000. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin. Infect. Dis. 30:870876.
24. Nord, C. E.,, P. O. Nystrom,, and B. Brismar. 1994. A comparative trial for intraabdominal infections of meropenem. Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D. C.
25. Oh, H.,, N. El Amin,, T. Davies,, P. C. Appelbaum,, and C. Edlund. 2001. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains. Antimicrob. Agents Chemother. 45:19771981.
26. Oh, H.,, C. E. Nord,, L. Barkholt,, M. Hedberg,, and C. Edlund. 2000. Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone. Infection. 28:272277.
27. Paradis, D.,, F. Vallee,, S. Allard,, C. Bisson,, N. Daviau,, C. Drapeau,, F. Auger,, and M. LeBel. 1992. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob. Agents Chemother. 36:20852092.
28. Plaisance, K. I.,, R. Quintiliani,, and C. H. Nightingale. 1998. The pharmacokinetics of metronidazole and its metabolites in critically ill patients.J. Antimicrob. Chemother. 21:195200.
29. Solomkin, J. S.,, D. L. Hemsell,, R. Sweet,, F. Tally,, and J. Bartlett. 1992. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. 15(Suppl. 1):S33S42.
30. Solomkin, J. S.,, H. H. Reinhart,, E. P. Dellinger,, J. M. Bohnen,, O. D. Rotstein,, S. B. Vogel,, H. H. Simms,, C. S. Hill,, H. S. Bjornson,, D. C. Haverstock,, H. O. Coulter,, and R. M. Echols. 1996. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann. Surg. 223:303315.
31. Solomkin, J. S.,, S. E. Wilson,, N. V. Christou,, O. D. Rotstein,, E. P. Dellinger,, R. S. Bennion,, R. Pak,, and K. Tack. 2001. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Ann. Surg. 233:7987.
31a. Solomkin, J. S.,, A. E. Yellin,, O. D. Rotstein. 2003. Results of a double-blind, randomized comparative phase III trial of ertapenem vs piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann. Surg. 237:235245.
32. Stratton, C. 1992. Fluoroquinolone antibiotics: properties of the class and individual agents. Clin. Ther. 14:347375.
33. Thadepalli, H.,, M. B. Bansal,, B. Rao,, R. See,, S. K. Chuah,, R. Marshall and,, V. K. Dhawan. 1988. Ciprofloxacin: in vitro, experimental, and clinical evaluation. Rev. Infect. Dis. 10:505515.
34. Whiting, J. L.,, N. Cheng,, A. W. Chow. 1987. Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against Gram-positive and Gram-negative anaerobic bacteria. Antimicrob. Agents Chemother. 31:13791382.
35. Wise, R.,, I. A. Donovan,, M. R. Lockley,, J. Drumm,, and J. M. Andrews. 1986. The pharmacokinetics and tissue penetration of imipenem. J. Antimicrob. Chemother. 18(Suppl. E):93101.
36. Zhanel, G. G.,, K. Ennis,, L. Vercaigne,, A. Walkty,, A. S. Gin,, J . Embil,, H. Smith,, and D. J. Hoban. 2002. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62:1359.

Tables

Generic image for table
Table 1

Organisms identified in three recently completed clinical trials in intra-abdominal infections

Citation: Solomkin J. 2003. Treatment of Intra-Abdominal Infections, p 217-225. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch12
Generic image for table
Table 2

The microbiology of treatment failure from two trials with quinols ones for intra-abdominal infections

Citation: Solomkin J. 2003. Treatment of Intra-Abdominal Infections, p 217-225. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch12
Generic image for table
Table 3

Reported susceptibilities of anaerobic bacteria to quinolones

Citation: Solomkin J. 2003. Treatment of Intra-Abdominal Infections, p 217-225. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch12
Generic image for table
Table 4

Gram-negative organisms identified in 100 patients with postoperative peritonitis

Citation: Solomkin J. 2003. Treatment of Intra-Abdominal Infections, p 217-225. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch12

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error